Athens, Greece and Charlottesville, VA.

Biovista has joined the European ACGT consortium developing advanced semantic technologies in support of post genomic clinical trials in cancer.

The aim of this work is to create an IT grid-based infrastructure that will support clinicians and bio-researchers in clinical trial design and research in two cancer modalities: Wilms tumor (child nephroblastoma) and breast cancer.

Biovista’s Discovery Algorithmics technology is being employed to better understand the disease mechanisms, help optimize trial design and patient cohorts, and help identify suitable biomarkers.